Moreover, CD45 expression level could not accurately distinguish BRM- from BMDMs-derived GAMs in glioma patient samples, suggesting the need for more sensitive and specific RNA-sequencing, flow cytometry, and other comprehensive analyses to distinguish further the gene expression differences between BRM- and BMDM-derived GAMs (36). This evidence concerns the gene PTPRC and central nervous system cancer.